What’s next for SINAPSE? A sneak peak into our R&D pipeline!

Innovation never stops at SINAPSE. To provide a more comprehensive diagnostic ecosystem, our team is working hard on developing two new, high-impact examination types:

• Angiography: scheduled for completion next year, expanding our capability to analyze complex vascular structures;
• Perfusion: now that the pre-feasibility study is behind us, development is moving full steam ahead with a target completion date late next year.

We continue to evolve, ensuring that advanced diagnostic technologies are smarter, faster and more accessible.

Expanding diagnostic capabilities into two new medical conditions – Hemorrhagic Stroke and Aneurysm

Building robust medical software requires rigorous science, strong backing, and continuous innovation. We are excited to share an update on our ongoing research and development as we expand our diagnostic capabilities into two critical medical conditions:

🧠  1. Hemorrhagic Stroke: research and development are actively underway. To ensure the highest accuracy and safety, we are currently gathering and analyzing additional clinical data to train and validate our algorithms.

🔴 2. Aneyrism: Thanks to recent financial support from state funding, our dedicated team officially kicked off this new project this August! Our goal is to complete the development and deliver this vital diagnostic tool by the summer of next year.

These milestones reflect our ongoing commitment to expanding the clinical utility of SINAPSE and bringing high-impact solutions to the global healthcare market.

Major milestone in SINAPSE’s development – we have officially initiated the CE Mark certification process

Medical technologies like SINAPSE are innovative but still must be safe, reliable and compliant to the strict European directives and regulations. This is fundamental to our principles – we are commited to ensure the highest possible quality, so we begun our path towards CE Mark certification.

In terms to lead us through this complex and demanding process, we have engaged BSI Group who is one of the world’s leading and most rigorous notified bodies, providing certification and auditing services.

We aim to finalize the process and receive the CE Mark in the spring of next year, and achieve the status of an officially certified medical device.